Ultrahuman, AXA, HSBC, MediPharm & more

Ultrahuman raises $17.5m 

Healthtech wearable glucose tracker Ultrahuman has raised $17.5 million in sequence B funding, bringing the entire funds the corporate has raised to this point to $25 million. 

Ultrahuman is a metabolic health platform that helps individuals create long-term habits and adjustments by way of deep well being insights, as an alternative choice to weight-reduction plan and strict train routines. The Ultrahuman Cyborg wearable, which launched in June this yr, helps individuals optimise their train and diet based mostly on glucose biomarkers. 

The sequence B funding got here from Alpha Wave Incubation (AWI), amongst others. Ultrahuman plans to make use of the funds for geographical growth and to enhance their biomarker expertise. 

Axa sells its Singapore enterprise to HSBC 

Insurance group Axa has introduced it’s promoting its Singapore enterprise to the HSBC banking group, in a deal value $575 million. 

Axa has made the sale following the corporate’s determination to withdraw from areas the place it lacks scale. 
The deal is HSBC’s largest acquisition since 2012, and would be the firm’s first step into the medical health insurance market. HSBC presently ranks tenth in life insurance coverage in Singapore. 

Antidote Health raises $12 million to arrange digital HMO

US telehealth firm Antidote Health has raised $12 million to construct an AI-based digital well being upkeep organisation (HMO). 

This will allow  uninsured and underinsured individuals to entry healthcare, by way of a wise chatbot and videocalling. Antidote Health selected the HMO mannequin based mostly on the truth that over 38 million individuals in America are uninsured. Health protection by means of Antidote is offered from $29 per 30 days. 

The firm launched in January with a 24/7 digital acute and first care service throughout New York, New Jersey, Florida, Michigan, and North Carolina. With this primary funding spherical, the corporate plans to develop nationwide. 

SomaLogic and Twist Bioscience Corporation accomplice to analysis antibodies

Biotech firms SomaLogic and Twist Bioscience have introduced a partnership that can allow them to create novel antibodies and analysis new medicine based mostly on key illness biomarkers.

Twist Bioscience manufactures artificial DNA-based merchandise for drug discovery. The collaboration will enable Twist to make use of the SomaScan® Platform to rapidly determine antibodies to deal with illness. 

Human blood proteins are the targets for medicine that deal with greater than 90% of ailments, and figuring out which of those proteins may very well be a candidate for a focused drug has historically been a problem for researchers. The SomaScan Platform generates lists of proteins concerned within the illness course of. 

MediPharm Labs Australia receives authorities grant to develop

Medical hashish firm MediPharm Labs has been awarded $330,000 as a part of the Australian Government’s $50 million fund to assist producers to scale their enterprise. 

MediPharm was based in 2015, specialising within the growth and manufacture of purified, pharmaceutical-quality hashish concentrates. MediPharm Labs Australia was established in 2017. 
The subsidiary intends to make use of the funds to extend the effectivity of its hashish purification system and improve the automation of its main packaging manufacturing course of, permitting the corporate to develop its rising home and worldwide consumer base, and meet the rise in demand for its merchandise.

Recommended For You

About the Author: Adrian

Leave a Reply